Carbapenem-Resistant Enterobacteriaceae Testing Market Report: Trends, Forecast and Competitive Analysis to 2031
상품코드:1859051
리서치사:Lucintel
발행일:2025년 11월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 카르바페넴 내성 장내 세균 검사 시장 전망은 병원 및 클리닉 시장에서의 기회로 인해 유망합니다. 세계 카르바페넴 내성 장내세균 검사 시장은 2025-2031년 9.9%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 크레아티닌 감염증 발생률 증가, 진단 기술의 발전, 감염 관리에 대한 규제 강화 등이 있습니다.
Lucintel의 예측에 따르면, 유형별로는 최소 감염 억제가 예측 기간 동안 높은 성장세를 보일 것으로 예측됩니다.
용도별로는 병원이 높은 성장이 예상됩니다.
지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예측됩니다.
카르바페넴 내성 장내 세균 검사 시장의 새로운 트렌드
카르바페넴 내성 장내세균 검사 시장은 항균제 내성으로 인한 전 세계적인 건강 위협에 힘입어 역동적인 변화를 겪고 있습니다. 이러한 새로운 트렌드는 진단 역량 강화, 워크플로우 간소화, 카르바페넴 내성 장내세균 검출 속도와 접근성 향상에 중점을 두고, 카르바페넴 내성 장내세균의 확산에 효과적으로 대응하는 것을 목표로 합니다.
신속 분자진단: 카르바페넴계 항균제 유전자를 며칠이 아닌 몇 시간 내에 검출할 수 있는 신속 분자진단 플랫폼에 대한 관심이 높아지고 있습니다. 이를 통해 카바페넴 내성 장내세균을 신속하게 식별할 수 있어 감염 관리 대책을 신속하게 시행하고 적절한 항생제를 적시에 투여할 수 있어 환자의 예후에 직접적인 영향을 미칠 수 있습니다.
POC 검사: POC(Point of Care)에 적합한 카바페넴 내성 장내세균 검사 솔루션 개발은 새로운 트렌드입니다. POCT는 중앙 검사기관에 샘플을 보낼 필요성을 줄이고, 환자의 침대 옆이나 소규모 클리닉에서 신속한 진단을 용이하게 합니다.
감시를 위한 차세대 시퀀싱: 감시를 목적으로 한 카르바페넴 내성 장내세균과 분리균의 상세한 유전체 특성 분석에 NGS의 활용이 증가하고 있습니다. 이를 통해 내성 메커니즘의 정확한 규명, 감염 경로 추적, 발병 역학 파악을 통해 카르바페넴 내성 장내세균의 확산을 억제하기 위한 공중보건 전략에 정보를 제공할 수 있습니다.
멀티플렉스 분석 : 여러 카바페네마제 유전자 및 기타 내성 마커를 동시에 검출할 수 있는 멀티플렉스 분석의 채택은 중요한 추세입니다. 이러한 분석은 한 번의 검사로 종합적인 정보를 제공하고, 검사의 복잡성을 줄이고, 진단 효율을 향상시키며, 더 많은 정보에 입각한 치료 방침을 결정할 수 있게 합니다.
자동화 및 하이스루풋 시스템: 카르바페넴 내성 장내세균과 세균 검사의 자동화 및 하이스루풋 시스템은 임상 실험실에서 널리 보급되고 있습니다. 이러한 추세는 검사 능력을 향상시키고, 수작업으로 인한 실수를 줄이고, 워크플로우의 효율성을 개선하여 실험실에서 더 많은 검체를 일관되고 신뢰할 수 있는 결과로 처리할 수 있도록 하는 것을 목표로 합니다.
이러한 추세는 보다 신속하고 접근성이 높으며 종합적인 진단 솔루션으로의 전환을 촉진하여 카르바페넴 내성 장내세균 검사 시장을 근본적으로 재편하고 있습니다. 이러한 솔루션은 신속한 임상적 판단을 가능하게 하고, 감염 관리 노력을 강화하며, 강력한 감시를 지원하고, 궁극적으로 항균제 내성을 퇴치하는 데 크게 기여할 것입니다.
카르바페넴 내성 장내세균 검사 시장의 최근 동향
카르바페넴 내성 장내 세균 검사 시장은 항생제 내성으로 인한 공중 보건 위협이 증가하고 진단 능력 향상에 대한 긴급한 필요성으로 인해 최근 몇 가지 중요한 추세를 목격하고 있습니다. 이러한 발전은 카르바페넴 내성 장내세균 검출의 속도, 정확성, 접근성을 향상시키는 것을 목표로 하고 있습니다.
신속 분자 검사의 상용화: 카르바페넴 내성 장내 세균에 대한 신속 분자진단 검사의 상용화와 채택 확대가 중요한 진전입니다. 이 검사는 임상 검체에서 직접 특정 카바페넴계 항균제 유전자(KPC, NDM, OXA-48 등)를 몇 시간 내에 확인할 수 있으며, 기존 배양에 기반한 방법에 비해 납기를 크게 단축할 수 있습니다.
새로운 표현형 분석법 개발: 최근 카르바페넴 불활성화법(CIM), 개량형 카르바페넴 불활성화법 등 새로운 표현형 분석법이 도입되고 있습니다. 이러한 저비용의 간편한 검사법은 임상 실험실에서 카르바페넴계 항생제 생산 확인에 널리 사용되고 있으며, 신뢰할 수 있는 결과를 제공합니다.
POC 기기에 대한 관심 증가: 카르바페넴 내성 장내 세균 검출을 위한 POC에 가까운, 또는 진정한 POC 기기의 개발 동향이 점점 더 높아지고 있습니다. 일부 복잡한 표적에 대해서는 아직 초기 단계이지만, 침대 옆에서 빠른 결과를 제공하고 감염 관리 조치 및 치료 시작을 즉시 가능하게 하는 데 중점을 두고 있습니다.
검사 자동화 시스템과의 통합: 각 제조업체는 기존 검사 자동화 시스템과 원활하게 통합할 수 있는 카바페넴 내성 장내 세균 검사 솔루션 개발에 점점 더 집중하고 있습니다. 이를 통해 높은 처리량 기능을 강화하고, 수작업을 줄이며, 인적 오류의 위험을 최소화하고, 전체 실험실의 효율성과 일관성을 향상시킬 수 있습니다.
감시 및 보고 플랫폼의 강화: 최근 동향으로는 카르바페넴 내성 장내세균의 실시간 감시 및 보고를 위한 보다 정교한 디지털 플랫폼의 구축이 포함됩니다. 이 플랫폼은 공중 보건 기관이 내성 추세를 모니터링하고, 발병 클러스터를 식별하고, 카르바페넴 내성 장내세균의 확산을 효과적으로 억제하기 위해 표적화된 개입을 시행하는 데 도움을 주고 있습니다.
이러한 시장 동향은 보다 신속하고 정확한 진단을 가능하게 하고, 조기 감염 관리를 촉진하며, 다양한 환경에서 검사 접근성을 개선하고, 실험실 워크플로우를 간소화하고, 공중보건 감시를 강화함으로써 카르바페넴 내성 장내세균 검사 시장에 종합적인 영향을 미치고, 항균제 내성 항균제 내성에 대한 보다 효과적인 대응에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 개요
배경과 분류
공급망
제3장 시장 동향과 예측 분석
업계 촉진요인과 과제
PESTLE 분석
특허 분석
규제 환경
제4장 세계의 카바페넴 내성 장내세균 검사 시장 : 유형별
개요
매력 분석 : 유형별
Modified Hodge : 동향과 예측(2019-2031년)
최소 감염 억제 : 동향과 예측(2019-2031년)
제5장 세계의 카바페넴 내성 장내세균 검사 시장 : 용도별
개요
매력 분석 : 용도별
병원 : 동향과 예측(2019-2031년)
클리닉 : 동향과 예측(2019-2031년)
기타 : 동향과 예측(2019-2031년)
제6장 지역 분석
개요
세계의 카바페넴 내성 장내세균 검사 시장 : 지역별
제7장 북미의 카바페넴 내성 장내세균 검사 시장
개요
북미의 카바페넴 내성 장내세균 검사 시장 : 유형별
북미의 카바페넴 내성 장내세균 검사 시장 : 용도별
미국의 카바페넴 내성 장내세균 검사 시장
멕시코의 카바페넴 내성 장내세균 검사 시장
캐나다의 카바페넴 내성 장내세균 검사 시장
제8장 유럽의 카바페넴 내성 장내세균 검사 시장
개요
유럽의 카바페넴 내성 장내세균 검사 시장 : 유형별
유럽의 카바페넴 내성 장내세균 검사 시장 : 용도별
독일의 카바페넴 내성 장내세균 검사 시장
프랑스의 카바페넴 내성 장내세균 검사 시장
스페인의 카바페넴 내성 장내세균 검사 시장
이탈리아의 카바페넴 내성 장내세균 검사 시장
영국의 카바페넴 내성 장내세균 검사 시장
제9장 아시아태평양의 카바페넴 내성 장내세균 검사 시장
개요
아시아태평양의 카바페넴 내성 장내세균 검사 시장 : 유형별
아시아태평양의 카바페넴 내성 장내세균 검사 시장 : 용도별
일본의 카바페넴 내성 장내세균 검사 시장
인도의 카바페넴 내성 장내세균 검사 시장
중국의 카바페넴 내성 장내세균 검사 시장
한국의 카바페넴 내성 장내세균 검사 시장
인도네시아의 카바페넴 내성 장내세균 검사 시장
제10장 기타 지역(ROW)의 카바페넴 내성 장내세균 검사 시장
개요
기타 지역 의 카바페넴 내성 장내세균 검사 시장 : 유형별
기타 지역 의 카바페넴 내성 장내세균 검사 시장 : 용도별
중동의 카바페넴 내성 장내세균 검사 시장
남미의 카바페넴 내성 장내세균 검사 시장
아프리카의 카바페넴 내성 장내세균 검사 시장
제11장 경쟁 분석
제품 포트폴리오 분석
운영 통합
Porter의 Five Forces 분석
경쟁 기업간 경쟁 관계
바이어의 교섭력
공급업체의 교섭력
대체품의 위협
신규 진출업체의 위협
시장 점유율 분석
제12장 기회와 전략 분석
밸류체인 분석
성장 기회 분석
성장 기회 : 유형별
성장 기회 : 용도별
세계의 카바페넴 내성 장내세균 검사 시장의 새로운 동향
전략 분석
신제품 개발
인증 및 라이선싱
인수합병(M&A), 계약, 제휴 및 합작투자(JV)
제13장 밸류체인 주요 기업 개요
경쟁 분석
TBA
SolGent
ELITechGroup
ALIFAX
BioMerieux
제14장 부록
그림 리스트
표 리스트
분석 방법
면책사항
저작권
약어와 기술 단위
Lucintel에 대해
문의
LSH
영문 목차
영문목차
The future of the global carbapenem-resistant enterobacteriaceae testing market looks promising with opportunities in the hospital and clinic markets. The global carbapenem-resistant enterobacteriaceae testing market is expected to grow with a CAGR of 9.9% from 2025 to 2031. The major drivers for this market are the increasing incidence of cre infections, the rising advancements in diagnostic technologies, and the growing regulatory emphasis on infection control.
Lucintel forecasts that, within the type category, minimal inhibitory is expected to witness higher growth over the forecast period.
Within the application category, hospital is expected to witness higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.
Emerging Trends in the Carbapenem-Resistant Enterobacteriaceae Testing Market
The carbapenem-resistant enterobacteriaceae testing market is undergoing dynamic changes, largely driven by the urgent global health threat posed by antimicrobial resistance. These emerging trends are focused on enhancing diagnostic capabilities, streamlining workflows, and improving the speed and accessibility of carbapenem-resistant enterobacteriaceae detection to combat its spread effectively.
Rapid Molecular Diagnostics: There's a strong trend towards rapid molecular diagnostic platforms capable of detecting carbapenems genes within hours, rather than days. This allows for quicker identification of carbapenem-resistant enterobacteriaceae, enabling faster implementation of infection control measures and timely administration of appropriate antibiotics, directly impacting patient outcomes.
Point-of-Care Testing: The development of carbapenem-resistant enterobacteriaceae testing solutions suitable for point-of-care settings is an emerging trend. POCT reduces the need for sending samples to centralized laboratories, facilitating quicker diagnosis at the patient's bedside or in smaller clinics, which is crucial for early intervention and preventing further transmission in various healthcare settings.
Next-Generation Sequencing for Surveillance: NGS is increasingly being utilized for detailed genomic characterization of carbapenem-resistant enterobacteriaceae isolates for surveillance purposes. This allows for precise identification of resistance mechanisms, tracking transmission routes, and understanding the epidemiology of outbreaks, informing public health strategies to contain the spread of carbapenem-resistant enterobacteriaceae.
Multiplex Assays: The adoption of multiplex assays capable of simultaneously detecting multiple carbapenemase genes and other resistance markers is a key trend. These assays offer comprehensive information from a single test, reducing testing complexity, improving diagnostic efficiency, and enabling more informed treatment decisions.
Automation and High-Throughput Systems: Automation and high-throughput systems are becoming more prevalent in clinical laboratories for carbapenem-resistant enterobacteriaceae testing. This trend aims to increase testing capacity, reduce manual errors, and improve workflow efficiency, allowing laboratories to process a larger volume of samples with consistent and reliable results.
These trends are fundamentally reshaping the carbapenem-resistant enterobacteriaceae testing market by driving towards faster, more accessible, and comprehensive diagnostic solutions. They enable quicker clinical decisions, enhance infection control efforts, support robust surveillance, and ultimately contribute significantly to the global fight against antimicrobial resistance.
Recent Developments in the Carbapenem-Resistant Enterobacteriaceae Testing Market
The carbapenem-resistant enterobacteriaceae testing market has recently witnessed several crucial developments, driven by the escalating public health threat of antibiotic resistance and the urgent need for improved diagnostic capabilities. These advancements are aimed at enhancing the speed, accuracy, and accessibility of carbapenem-resistant enterobacteriaceae detection.
Commercialization of Rapid Molecular Tests: A significant development is the commercialization and increased adoption of rapid molecular diagnostic tests for carbapenem-resistant enterobacteriaceae. These tests can identify specific carbapenems genes (e.g., KPC, NDM, OXA-48) directly from clinical samples in a few hours, drastically reducing turnaround time compared to traditional culture-based methods.
Development of Novel Phenotypic Assays: Recent years have seen the introduction of new phenotypic assays, such as carbapenem inactivation methods (CIM) and modified carbapenem inactivation methods. These low-cost, easy-to-perform tests are becoming more widely adopted for confirming carbapenems production in clinical laboratories, offering reliable results.
Increased Focus on Point-of-Care Devices: There's a growing trend in the development of near point-of-care or even true point-of-care devices for carbapenem-resistant enterobacteriaceae detection. While still in early stages for some complex targets, efforts are focused on providing rapid results at the bedside, enabling immediate infection control measures and treatment initiation.
Integration with Laboratory Automation Systems: Manufacturers are increasingly focusing on developing carbapenem-resistant enterobacteriaceae testing solutions that seamlessly integrate with existing laboratory automation systems. This enhances high-throughput capabilities, reduces manual labor, and minimizes the risk of human error, improving overall laboratory efficiency and consistency.
Enhanced Surveillance and Reporting Platforms: Recent developments include the creation of more sophisticated digital platforms for real-time surveillance and reporting of carbapenem-resistant enterobacteriaceae cases. These platforms aid public health agencies in monitoring resistance trends, identifying outbreak clusters, and implementing targeted interventions to control the spread of carbapenem-resistant enterobacteriaceae effectively.
These developments are collectively impacting the carbapenem-resistant enterobacteriaceae testing market by enabling faster and more accurate diagnosis, facilitating earlier infection control, improving accessibility of testing in diverse settings, streamlining laboratory workflows, and strengthening public health surveillance, all contributing to a more effective response against antimicrobial resistance.
Strategic Growth Opportunities in the Carbapenem-Resistant Enterobacteriaceae Testing Market
The carbapenem-resistant enterobacteriaceae testing market offers significant strategic growth opportunities across various key applications, driven by the escalating global burden of antimicrobial resistance and the critical need for rapid, accurate diagnostics. Capitalizing on these application-specific demands will be vital for market players.
Hospital and Clinical Diagnostics: The primary growth opportunity lies in equipping hospitals and clinical laboratories with advanced carbapenem-resistant enterobacteriaceae testing solutions. Rapid and accurate identification is crucial for timely patient management, preventing healthcare-associated infections, and implementing effective isolation protocols to contain outbreaks within healthcare facilities.
Infection Control and Surveillance Programs: Governments and healthcare organizations are investing heavily in national and regional infection control and surveillance programs. This presents a major growth opportunity for carbapenem-resistant enterobacteriaceae testing, as diagnostics are fundamental for monitoring resistance trends, identifying high-risk areas, and guiding public health interventions.
Pharmaceutical and Biotech R&D: The development of new antibiotics and therapeutic strategies against carbapenem-resistant enterobacteriaceae requires extensive testing during preclinical and clinical trials. This creates a niche but significant growth opportunity for specialized carbapenem-resistant enterobacteriaceae testing services and kits that can accurately assess the efficacy of novel antimicrobial compounds.
Veterinary Diagnostics: While human health is the primary focus, the "One Health" approach recognizes the link between human and animal health. Growing awareness of antimicrobial resistance in livestock and companion animals presents an emerging opportunity for carbapenem-resistant enterobacteriaceae testing in veterinary diagnostics to monitor and control resistance spread.
Point-of-Care and Decentralized Testing: The push for decentralized healthcare and rapid decision-making creates opportunities for compact, easy-to-use carbapenem-resistant enterobacteriaceae testing devices suitable for smaller clinics, emergency rooms, or even remote settings. This expands accessibility and reduces turnaround times, crucial for immediate patient management and infection control.
These strategic growth opportunities are profoundly impacting the carbapenem-resistant enterobacteriaceae testing market by driving the development of specialized and versatile diagnostic solutions tailored to the unique needs of each application. This leads to increased innovation, diversified product portfolios, and expanded market reach, ultimately strengthening the global response to antimicrobial resistance.
Carbapenem-Resistant Enterobacteriaceae Testing Market Driver and Challenges
The carbapenem-resistant enterobacteriaceae testing market's trajectory is shaped by a complex interplay of various technological, economic, and regulatory factors. Major drivers stem from the urgent global health threat of antimicrobial resistance, while challenges include high testing costs, the technical complexity of emerging methods, and stringent regulatory pathways.
The factors responsible for driving the carbapenem-resistant enterobacteriaceae testing market include:
1. Rising Global Incidence of carbapenem-resistant enterobacteriaceae Infections: The escalating prevalence of carbapenem-resistant enterobacteriaceae infections worldwide is the most significant driver. These "superbugs" cause severe, often untreatable infections, leading to higher morbidity and mortality rates, thereby creating an urgent and growing demand for rapid and accurate diagnostic tools to combat their spread.
2. Increasing Awareness and Surveillance Initiatives: Greater awareness among healthcare professionals and the public about the dangers of carbapenem-resistant enterobacteriaceae, coupled with increased national and international surveillance programs, is driving market growth. These initiatives emphasize early detection and reporting, boosting the demand for effective testing solutions to monitor and control resistance.
3. Technological Advancements in Diagnostics: Continuous innovation in diagnostic technologies, particularly in molecular assays (PCR, NGS) and automated phenotypic methods, is a key driver. These advancements offer improved sensitivity, specificity, and faster turnaround times, enabling more precise and timely identification of carbapenem-resistant enterobacteriaceae, which directly impacts treatment decisions.
4. Growing Healthcare Expenditure: Increased healthcare spending, particularly in developing nations, contributes to market expansion. As healthcare infrastructure improves and access to advanced diagnostics becomes more widespread, there's a greater capacity and willingness to invest in carbapenem-resistant enterobacteriaceae testing technologies to improve patient outcomes and infection control.
5. Antimicrobial Stewardship Programs: The global push for antimicrobial stewardship programs aims to optimize antibiotic use and curb resistance. carbapenem-resistant enterobacteriaceae testing plays a critical role by guiding appropriate antibiotic selection, preventing empirical broad-spectrum treatment, and supporting infection control measures, thereby fostering responsible antibiotic use.
Challenges in the carbapenem-resistant enterobacteriaceae testing market are:
1. High Cost of Advanced Technologies: The significant upfront cost of advanced molecular diagnostic platforms and reagents can be a major challenge, especially for healthcare facilities in resource-limited settings. This high investment can limit widespread adoption, despite the clinical benefits of rapid and accurate carbapenem-resistant enterobacteriaceae detection.
2. Technical Complexity and Skilled Personnel: Many advanced carbapenem-resistant enterobacteriaceae testing methods, particularly molecular and genomic techniques, require specialized equipment, complex protocols, and highly trained laboratory personnel for accurate execution and interpretation. A shortage of skilled staff can hinder the effective implementation and widespread use of these diagnostics.
3. Regulatory and Reimbursement Hurdles: The development and commercialization of new carbapenem-resistant enterobacteriaceae diagnostic tests face stringent regulatory approval processes, which can be time-consuming and costly. Additionally, securing adequate reimbursement from healthcare payers for these tests can be a challenge, impacting their market penetration and accessibility.
These drivers and challenges on the carbapenem-resistant enterobacteriaceae testing market is a dynamic push for more rapid, accurate, and accessible diagnostics to combat the escalating threat of antimicrobial resistance. However, overcoming the hurdles of cost, technical complexity, and regulatory pathways remains critical for achieving widespread adoption and maximizing the public health benefit of these essential tests.
List of Carbapenem-Resistant Enterobacteriaceae Testing Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies carbapenem-resistant enterobacteriaceae testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the carbapenem-resistant enterobacteriaceae testing companies profiled in this report include-
TBA
SolGent
ELITechGroup
ALIFAX
BioMerieux
Carbapenem-Resistant Enterobacteriaceae Testing Market by Segment
The study includes a forecast for the global carbapenem-resistant enterobacteriaceae testing market by type, application, and region.
Carbapenem-Resistant Enterobacteriaceae Testing Market by Type [Value from 2019 to 2031]:
Modified Hodge
Minimal Inhibitory
Carbapenem-Resistant Enterobacteriaceae Testing Market by Application [Value from 2019 to 2031]:
Hospitals
Clinics
Others
Carbapenem-Resistant Enterobacteriaceae Testing Market by Region [Value from 2019 to 2031]:
North America
Europe
Asia Pacific
The Rest of the World
Country Wise Outlook for the Carbapenem-Resistant Enterobacteriaceae Testing Market
The carbapenem-resistant enterobacteriaceae testing market is experiencing robust growth driven by the escalating global prevalence of these highly resistant "nightmare bacteria" and the urgent need for rapid, accurate diagnostics. Recent developments focus on improving detection speed, specificity, and accessibility of testing, crucial for timely treatment and effective infection control. This evolution is underpinned by a global commitment to combating antimicrobial resistance and enhancing public health surveillance.
United States: The US market is characterized by a strong emphasis on rapid molecular diagnostics and advanced automated systems for carbapenem-resistant enterobacteriaceae detection, driven by the CDC's focus on antimicrobial resistance. Significant investment in R&D aims to provide faster turnaround times for results, crucial for managing outbreaks and guiding appropriate treatment in healthcare settings.
China: China carbapenem-resistant enterobacteriaceae testing market is rapidly expanding due to increasing awareness, growing healthcare expenditure, and a rising incidence of antibiotic-resistant infections. There's a dual focus on developing indigenous diagnostic solutions and adopting international technologies to strengthen its capacity for rapid and accurate carbapenem-resistant enterobacteriaceae identification.
Germany: Germany market for carbapenem-resistant enterobacteriaceae testing prioritizes high-quality, reliable diagnostic platforms, integrating seamlessly with its advanced healthcare infrastructure. Developments include sophisticated molecular assays and phenotypic tests, supporting comprehensive antimicrobial stewardship programs and robust surveillance efforts to control resistance.
India: India carbapenem-resistant enterobacteriaceae testing market is witnessing significant growth, spurred by a large patient population, improving healthcare facilities, and a growing burden of antibiotic resistance. There's an increasing demand for cost-effective and rapid diagnostic solutions, including both conventional and molecular methods, to address the challenge of carbapenem-resistant enterobacteriaceae in diverse clinical settings.
Japan: Japan carbapenem-resistant enterobacteriaceae testing market emphasizes precision and technological innovation, with a focus on advanced molecular diagnostics for rapid identification of carbapenems genes. Developments are geared towards highly sensitive and specific tests to support strict infection control measures and facilitate prompt, targeted treatment strategies in its healthcare system.
Features of the Global Carbapenem-Resistant Enterobacteriaceae Testing Market
Market Size Estimates: Carbapenem-resistant enterobacteriaceae testing market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Carbapenem-resistant enterobacteriaceae testing market size by type, application, and region in terms of value ($B).
Regional Analysis: Carbapenem-resistant enterobacteriaceae testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, applications, and regions for the carbapenem-resistant enterobacteriaceae testing market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the carbapenem-resistant enterobacteriaceae testing market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the carbapenem-resistant enterobacteriaceae testing market by type (modified hodge and minimal inhibitory), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Carbapenem-Resistant Enterobacteriaceae Testing Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Modified Hodge: Trends and Forecast (2019-2031)
4.4 Minimal Inhibitory: Trends and Forecast (2019-2031)
5. Global Carbapenem-Resistant Enterobacteriaceae Testing Market by Application
5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Hospitals: Trends and Forecast (2019-2031)
5.4 Clinics: Trends and Forecast (2019-2031)
5.5 Others: Trends and Forecast (2019-2031)
6. Regional Analysis
6.1 Overview
6.2 Global Carbapenem-Resistant Enterobacteriaceae Testing Market by Region
7. North American Carbapenem-Resistant Enterobacteriaceae Testing Market
7.1 Overview
7.2 North American Carbapenem-Resistant Enterobacteriaceae Testing Market by Type
7.3 North American Carbapenem-Resistant Enterobacteriaceae Testing Market by Application
7.4 United States Carbapenem-Resistant Enterobacteriaceae Testing Market
